Application of Anlotinib Combined With Neoadjuvant Chemotherapy in Primary EWS/PNET of Lung: A Case Report

Abstract

Primary pulmonary EWS/PNET(PPES) is extremely rare and is associated with a poor prognosis. Tumor angiogenesis plays an important role in tumor, so it has become a hot topic in molecular targeted therapy. Anlotinib is a new oral small molecular multi-targeted receptor tyrosine kinase (RTK) inhibitor. This report describes a 20 year-old man with PPES. After 4 neoadjuvant chemotherapy cycles (VACwith alternating IE) combined with anlotinib, the left total pneumonectomy was performed. Then maintenance anlotinib monotherapy was continued, no sign of recurrence to date as an outcome. To our knowledge, this is the first demonstration of anlotinib combined with neoadjuvant chemotherapy efficacy in PPES.

18F-fluorodeoxyglucose positron emission tomography / computed tomography in primary Ewing sarcoma of the lung

“…According to Dharmalingam et al [3], "Primary Ewing sarcoma of the lung is anecdotally rare, with few cases reported in the literature" until 2020. The "Ewing family of tumors" includes other tissue types, such as soft tissue origin classified as extraosseous Ewing sarcoma or primitive neuroendocrine origin [2]. Because of the rarity of extraosseous Ewing sarcomas, the therapeutic approach is the same as for osseous ones [7].…”

“…This kind of tumor often occurs under 25, but the congenital presentation of extraosseous Ewing sarcoma, although it is exceedingly rare, reported Haas et al (2019) [1]. Multiple loci of soft tissue Ewing sarcomas develop at multiple localization: lungs [2][3][4][5][6], liver [7], and extremely rarely, primary Ewing sarcoma occurs in the female genital organs in the uterus [8].…”

Primary pulmonary Ewing sarcoma: a rare case report

“…Extra-bone localization of ES is less frequently observed [1][2][3]. The first case of primary ES of the lung was described by Hammar et al [4] in 1989, and since then, less than 40 cases have been reported in the literature [5]. It features a distinctive immunophenotype that combines diffuse and membranous CD99 expression with FLI-1 nuclear positivity [6].…”